Establishment Labs Holdings Inc. (NASDAQ:ESTA) Receives Average Rating of "Moderate Buy" from Analysts

Key Points

• Establishment Labs Holdings Inc. has received an average analyst rating of "Moderate Buy" with five brokers recommending to buy, one to hold, and one to sell the stock.
• The average price target set by analysts for Establishment Labs is $56.50, with a recent bullish outlook from Mizuho increasing their target to $70.00.
• Despite a year-over-year revenue increase of 16.1%, the company reported a loss of ($0.57) earnings per share, missing analysts' expectations for the recent quarter.

Establishment Labs Holdings Inc. (NASDAQ:ESTA - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the seven brokerages that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $56.50.

A number of equities analysts have weighed in on ESTA shares. Needham & Company LLC reissued a "buy" rating and set a $48.00 price objective on shares of Establishment Labs in a research note on Friday, June 13th. Citigroup boosted their price objective on Establishment Labs from $38.00 to $47.00 and gave the stock a "neutral" rating in a research note on Wednesday, July 9th. Mizuho boosted their price objective on Establishment Labs from $58.00 to $70.00 and gave the stock an "outperform" rating in a research note on Wednesday, July 16th. Wall Street Zen raised Establishment Labs from a "sell" rating to a "hold" rating in a research note on Saturday, September 20th. Finally, Canaccord Genuity Group started coverage on Establishment Labs in a research note on Wednesday, August 20th. They set a "buy" rating and a $60.00 price objective on the stock.

Hedge Funds Weigh In On Establishment Labs

Large investors have recently modified their holdings of the business. ANTIPODES PARTNERS Ltd acquired a new position in shares of Establishment Labs in the 1st quarter valued at $81,000. Osaic Holdings Inc. lifted its stake in shares of Establishment Labs by 900.0% in the 2nd quarter. Osaic Holdings Inc. now owns 2,000 shares of the company's stock valued at $85,000 after purchasing an additional 1,800 shares during the last quarter. CWM LLC lifted its stake in shares of Establishment Labs by 45.9% in the 2nd quarter. CWM LLC now owns 2,182 shares of the company's stock valued at $93,000 after purchasing an additional 686 shares during the last quarter. Elevation Point Wealth Partners LLC acquired a new position in shares of Establishment Labs in the 1st quarter valued at $207,000. Finally, Patriot Financial Group Insurance Agency LLC acquired a new position in shares of Establishment Labs in the 1st quarter valued at $234,000. Institutional investors and hedge funds own 72.91% of the company's stock.

Establishment Labs Stock Performance

Shares of NASDAQ:ESTA opened at $41.43 on Monday. The company has a debt-to-equity ratio of 9.71, a current ratio of 2.84 and a quick ratio of 1.67. The business's 50 day moving average price is $39.81 and its 200-day moving average price is $38.03. The firm has a market capitalization of $1.20 billion, a PE ratio of -13.58 and a beta of 0.85. Establishment Labs has a 1 year low of $26.56 and a 1 year high of $50.85.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.54) by ($0.03). The firm had revenue of $51.30 million during the quarter, compared to analyst estimates of $50.80 million. Establishment Labs had a negative return on equity of 224.34% and a negative net margin of 49.89%.The business's revenue was up 16.1% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.62) earnings per share. Establishment Labs has set its FY 2025 guidance at EPS. As a group, equities research analysts expect that Establishment Labs will post -2.41 earnings per share for the current fiscal year.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.